Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|October 17, 2011
vRad Announces Clinical Trials Partnership With ICON Medical Imaging
Advertisement
Virtual Radiologic
(vRad), a technology-enabled national radiology practice, has announced a premier radiology partnership with
ICON Medical Imaging
(ICON), the medical imaging division of ICON plc.
ICON Medical Imaging provides medical imaging-based product development services to the pharmaceutical biotechnology and medical device industries. The partnership with vRad will enable ICON Medical Imaging to access the breadth and depth of vRad's subspecialty expertise and to obtain high-quality interpretations provided by vRad's fellowship-trained radiologists.
The first clinical trial involving vRad launched in September, with more expected to rapidly follow. This partnership will provide a great opportunity for vRad radiologists to make an impact on advancing healthcare. The use of imaging in clinical trials has been recognized by the pharmaceutical industry to assist in measuring early results, thereby helping to shorten the timeline for bringing effective drugs to market, and saving costs and lives in the process.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5